Search for a trial

Ascending single dose study of the safety, tolerability, and pharmacokinetics of PRM-151 administered to healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF)

PRM-151 is being developed for potential therapeutic uses to prevent, treat, and reduce fibrosis. This study will provide an initial assessment of the safety, tolerability, and pharmacokinetics (PK) of PRM-151 after administration of ascending…

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock

To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.